Who Paid My Doc
Andrew Brill
Urogynecology and Reconstructive Pelvic Surgery San Francisco, CA Medical Doctor
NPI 1225055205 CMS profile 146678
3700 California St, Ground Floor, San Francisco, CA 94118
General payments
$345,343
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Andrew Brill of San Francisco, CA is reported in the CMS Open Payments database as having received $345,343 across 118 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $30,055 | 2 | |
| 2024 | General | $35,000 | 1 | |
| 2023 | General | $60,071 | 3 | |
| 2022 | General | $72,279 | 6 | |
| 2021 | General | $77,133 | 9 | |
| 2019 | General | $70,805 | 97 |
Beside peers
- Andrew Brill
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Andrew Brill were reported at $30,055. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.
Show as a table
| Year | Andrew Brill | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $70,805 | $799 | $319–$2,013 | $163 |
| 2020 | $0 | $384 | $158–$1,360 | $114 |
| 2021 | $77,133 | $641 | $247–$2,515 | $132 |
| 2022 | $72,279 | $843 | $347–$2,794 | $149 |
| 2023 | $60,071 | $819 | $308–$2,302 | $160 |
| 2024 | $35,000 | $882 | $306–$2,459 | $164 |
| 2025 | $30,055 | $779 | $301–$2,705 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
118 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in California
Jennifer Gruenenfelder
Urogynecology and Reconstructive Pelvic Surgery · Orange, CA
Seshadri Kasturi
Urogynecology and Reconstructive Pelvic Surgery · Sacramento, CA
Anne Ackerman
Urogynecology and Reconstructive Pelvic Surgery · Los Angeles, CA
Poone Shoureshi
Urogynecology and Reconstructive Pelvic Surgery · Laguna Hills, CA
Saad Juma
Urogynecology and Reconstructive Pelvic Surgery · Encinitas, CA
Leah Nakamura
Urogynecology and Reconstructive Pelvic Surgery · Laguna Hills, CA
Related records
Urogynecology and Reconstructive Pelvic Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.